According to the information received, this case seems to be an angioedema which is a well-known and documented adverse effect of dermal fillers.
Additionally, the risk of such adverse event is also mentioned in the instructions for use of our products.
Batch analyses undertaken confirms that the products passed sterility and quality compliance tests, therefore the imputability of the product seems dismissed.
|
According to the received information, the patient was injected on (b)(6) 2021 with teosyal rha 2 in the lips (rc/2109083).
She was also injected on (b)(6) 2021 with teosyal puresense ultra deep in the zygomatic malars (rc/2109084) and teosyal rha 4 in the zygomatic malars and soof (rc/2109085).
Starting on (b)(6) 2021, the patient developed severe edema, induration, redness, with sensation of heat, appearing at all injection sites.
She then developed an angioedema.
Initial treatments included a regimen of oral corticosteroids, antihistamines and antibiotic therapy.
Afterwards, redness of the chin area decreased but the edema and induration persisted both in the chin and in the other injected areas.
The diagnosis of angioedema was confirmed on (b)(6) 2021, which updated the reportability of this case.
On 04 october 2021, we received confirmation about the complete resolution of the adverse event.
|